The DJS Law Group is organizing the litigation, which centers on alleged violations of the Securities Exchange Act. According to the court filing, PROCEPT BioRobotics pulled sales forward from future periods to meet short-term revenue targets, a strategy that the plaintiffs argue rendered the company’s public financial disclosures materially misleading. Shareholders who acquired PRCT stock during the specified class period now face a September 22, 2026, deadline to seek lead plaintiff status.

David J. Schwartz, who leads the firm’s advocacy efforts, specializes in corporate governance and securities litigation. While the firm encourages affected investors to come forward to participate in the recovery process, they note that individual shareholders are not required to serve as lead plaintiffs to remain eligible for potential damages. The case remains a focal point for those seeking to address the impact of the company's accounting practices on their investment portfolios.